Vol 6, No 4 (2010)
Other materials agreed with the Editors
Published online: 2010-12-16
Letter to Editor
Onkol. Prak. Klin 2010;6(4):216-216.
Abstract
Not available
References
- Sjöblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001; 61(15): 5778–5783.
- Kerob D, Pedeutour F, Leboeuf C, et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol. 2008; 26(10): 1757–1759.
- Wang J, Morimitsu Y, Okamoto S, et al. COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans. J Mol Diagn. 2000; 2(1): 47–52.
- Rutkowski P, Van Glabbeke M, Rankin CJ, et al. European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group, Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010; 28(10): 1772–1779.
- Rutkowski P, Dębiec-Rychter M, Nowecki Zi, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol. 2011; 25(3): 264–270.